Nano4 Global has been selected for the SME Instrument Phase 2 initiative of Horizon 2020, a very competitive initiative. It was one of the few companies from life science field to be selected.
MagicCELLGene aims at developing a disruptive new technology DNA/RNAi transfection - magiccellgene.wixsite.com/magiccellgene. MagicCELLGene focus on the site directed magnetic hyperthermia that creates focal hotspots on the cell membrane to allow the entry of therapeutic nucleic acids, with potential clinical applications in cell-based gene therapy.
